In the future, the accuracy of the predictions could further be improved by considering the premorbidity of patient groups (e.g., hypertension), different phenotypes of fibroblasts (e.g., myofibroblasts), negative regulators for collagen degradation (e.g., MMP9), and collagen feedback to epithelial cells for regrowth and wound healing and to immune cells for transport properties through the evolving ECM. This evidence concerns the gene MMP9 and hypertensive disorder.